Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Silenseed signs $7.8 million agreement with GIBF to create Chinese subsidiary
Aug 1, 2017
Israeli Biomed Firm Silenseed Raises $10M
Jul 30, 2017
Silenseed Phase II pancreatic cancer drug trial to begin
Nov 10, 2015
Silenced: RNA biotech Silenseed withdraws $35 million IPO
Jun 13, 2014
Cancer biotech Silenseed files for a $35 million IPO
Silenseed is a clinical-stage biopharmaceutical company that is using a proprietary RNA interference strategy to develop cancer drugs and delivery systems designed to effectively penetrate and treat malignant solid tumors.
The companys novel drugs, combined with the local drug eluter (LODER) delivery system, have the potential to become an effective treatment for solid tumor cancers. Silenseed is focused on treatments for pancreatic cancer, prostate cancer, and certain brain cancers.
Silenseed has completed a phase 2a clinical study for pancreatic cancer which showed promising results.